Reports Q3 revenue $2.37M, consensus $2.1M. “While we believe istisociclib has provided benefit to a small number of patients in the Phase 1/2 trial, the emerging profile in patients with platinum-resistant ovarian cancer suggests an unfavorable risk-benefit profile and does not warrant further clinical development,” said Norbert Bischofberger, Ph.D., chief executive officer. “We are very grateful to the patients, caregivers and medical staff who dedicated their time and energy to make this clinical trial possible and your commitment to evaluating novel approaches to treat cancer.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRON:
- Kronos Bio files $250M mixed securities shelf
- Kronos Bio to present data at ASH annual meeting on p300 KAT inhibitor program
- KRON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Kronos Bio announces preclinical data from p300 KAT inhibitor program
- Kronos Bio to present data from p300 KAT inhibitor program
Questions or Comments about the article? Write to editor@tipranks.com